Skip to content

Colorado’s first licensed cannabis R&D firm to study marijuana’s effect on Alzheimer’s disease

March 6, 2020 / Arfinn Med MD /

Colorado’s first licensed cannabis R&D firm to study marijuana’s effect on Alzheimer’s disease

A Denver-based company hopes to be the state’s first to study the effects of marijuana on Alzheimer’s disease, thanks to a newly available research and development license in the city.

MedPharm Holdings plans to apply for a Denver marijuana R&D license to test delta-9 tetrahydrocannabinol (THC), cannabidiol (CBD) and other cannabinoids’ effects on Alzheimer’s and dementia patients.

According to the Alzheimer’s Association, 5.8 million Americans have the disease, a degenerative brain disorder that affects a person’s memory and thinking skills. While there are drugs that help ease symptoms, they do not change the course of the disease.

Albert Gutierrez, CEO of MedPharm, sees Alzheimer’s as “one of the biggest things that’s plaguing our country now and in the future.” That’s why he’s excited about cannabis’ potential to treat it.

Read Full Article Here

Stories you may be interested in

Survey of oncologists finds knowledge gap on medical marijuana

As more states legalize medical marijuana, two key groups — researchers whose job is it to understand its benefits and drawbacks, and physicians charged with advising potential users — are struggling to catch up with policymakers. Ilana Braun, an assistant professor of psychiatry at Harvard Medical School and chief of the division of adult psychosocial…
Read More →

PTSD and Cannabis

Post-Traumatic Stress Disorder (PTSD) is a psychiatric disorder that occurs in people who witnessed or have gone through a traumatic event.  That can include events such as  natural disasters, war/combat, a serious accident, or personal assault, among others.  People suffering from PTSD have disturbing thoughts and feelings related to the traumatic event that can last…
Read More →

COVID-19 and medical cannabis patients: What you need to know

In the midst of the COVID-19 maelstrom, the recent shuttering of nonessential stores has created concern around access to cannabis, particularly for medicinal cannabis consumers. Those who depend on cannabis for therapeutic purposes will be relieved to learn that across the US, medical cannabis dispensaries have been deemed essential services, comparable to pharmacies. As of March…
Read More →

Insomnia: A Silent Epidemic

The struggle to get a good night’s sleep is something many adults can relate to, but what if there was a natural alternative to keep those sheep jumping all night long? CBD, also known as cannabidiol, has been gaining popularity among patients to help treat pain, anxiety and so much more. Additionally, conditions such as…
Read More →

Arfinn Med March Updates

We are very happy to announce the release of several new functions within the Arfinn Med Platform.  Those include: * Text message updates from patients regarding their treatments * Templating for exam notes  * Updated analytics and dosing reports * Google calendar and Calendly integrations to schedule appointments. Please view the video below for more…
Read More →

Medical marijuana advocates concerned over recreational cannabis proposals

ALBUQUERQUE, N.M.— Some medical marijuana patients are concerned the proposed framework for legalizing recreational marijuana could have a potentially negative impact on the medical cannabis program. “It’s something that will devastate the medical program in doing so,” said Jason Barker, a medical cannabis advocate with Safe Access New Mexico. A special task force delivered a…
Read More →

Leave a Comment

You must be logged in to post a comment.